Alan P. Fields, Ph.D., leads a research laboratory at Mayo Clinic with interests in the genetics, biochemistry and cell biology of lung, ovarian, head and neck, and related cancers. Dr. Fields' lab is included in the Women's Cancer and Experimental Therapeutics programs within the Mayo Clinic Cancer Center.
Currently, the laboratory is focused on the role that members of the protein kinase C (PKC) family of protein kinases play in the initiation, promotion and metastatic spread of these cancers. Dr. Fields' team has developed cell and mouse models to help understand how specific PKC isozymes are involved in lung carcinogenesis.
The results from these studies demonstrate that multiple PKC isozymes play critical roles in cancer development (carcinogenesis). The team has identified one PKC isozyme, PKCι, that is a major oncogenic driver of multiple forms of cancer, including lung, ovarian, and head and neck cancers. Current studies are focused on developing genetically engineered preclinical models of PKCι-driven cancer in order to define the specific molecular mechanisms by which this oncogene drives tumorigenesis, and to evaluate novel therapeutic intervention strategies targeting PKCι for improved treatment of these cancers. In this regard, Dr. Fields has identified a highly potent and selective PKCι inhibitor and is currently evaluating its clinical efficacy in patients with lung and ovarian cancer.
Significance to patient care
Results from Dr. Fields' laboratory-based investigations have led to clinical testing of a novel therapeutic agent that inhibits PKCι as a treatment for lung and ovarian cancer.
- Named, Investigator of the Year, Mayo Clinic, Jacksonville, Florida, 2020